Loading...
•
Sep 30, 2023
Amneal Q3 2023 Earnings Report
Reported strong double-digit revenue and adjusted EBITDA growth and raised full year guidance.
Key Takeaways
Amneal Pharmaceuticals reported a strong Q3 2023 with a 14% increase in net revenue to $620 million and a 22% increase in adjusted EBITDA to $154 million. Net income attributable to Amneal Pharmaceuticals, Inc. was $10 million, compared to a net loss of $3 million in the third quarter of 2022. Diluted EPS was $0.06, and adjusted diluted EPS was $0.19. The company affirmed its previously announced increased full-year guidance.
Net revenue for Q3 2023 was $620 million, a 14% increase compared to Q3 2022.
Net income attributable to Amneal Pharmaceuticals, Inc. was $10 million in Q3 2023, compared to a net loss of $3 million in Q3 2022.
Adjusted EBITDA for Q3 2023 was $154 million, a 22% increase compared to Q3 2022.
Diluted EPS for Q3 2023 was $0.06, compared to a loss of $0.02 for Q3 2022.
Amneal
Amneal
Amneal Revenue by Segment
Revenue by Segment
Affordable Medicines Revenue
CapyFin.comSpecialty Revenue
CapyFin.comAvKARE Revenue
CapyFin.com Forward Guidance
Amneal affirmed its previously announced increased 2023 full year guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income